J. Feuillard et al., Inducible loss of NF-kappa B activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes, BLOOD, 95(6), 2000, pp. 2068-2075
The Epstein-Barr virus (EBV)-encoded latent membrane protein-1 induces NF-k
appa B activity by targeting I kappa B alpha. To understand the role of NF-
kappa B activation in EBV-related oncogenesis, we have subcloned mutated (I
kappa B alpha(32/36A) cDNA into a pHEBo vector containing doxycycline regu
latory sequences and stably transfected this construct into a lymphoblastoi
d cell line. Two tightly regulated clones were obtained in which I kappa B
alpha(32/36A) was inducible in a doxycycline dose-dependent manner. Levels
of inducible I kappa B alpha(32/36A) peaked at day 2, inhibition of NF-KB a
ctivity was closely correlated with levels of inducible I kappa B alpha(32/
36A) Levels of 3 well-known NF-kappa B-dependent genes, CD54,p105,and endog
enous I kappa B alpha, were decreased when (I kappa B alpha(32/36A) was ind
uced, and the growth of I kappa B alpha(32/36A)-induced EBV-infected cells
was slightly reduced. Loss of NF-kappa B activity was associated with decre
ased Bcl-2 protein levels. Finally, the induction of apoptosis was strongly
increased In I kappa B alpha(32/36A)-overexpressing cells. Together these
results show that it is possible to control I kappa B alpha(32/36A) levels
is, NF-kappa B activity, in EBV-infected B-lymphocytes using a doxycycline-
inducible vector. Moreover, our results indicate that NF-kappa B can protec
t EBV-infected cells from apoptosis by Bcl-2. Finally, our results suggest
that a cellular model with doxycycline-inducible I kappa B alpha 32/36A may
be useful in the identification of genuine NF-kappa B target genes in EBV-
infected B cells. (C) 2000 by The American Society of Hematology.